©2024 Stanford Medicine
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Not Recruiting
Trial ID: NCT01777152
Purpose
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the
efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care
CHOP in patients with CD30-positive mature T-cell lymphomas.
Official Title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Stanford Investigator(s)
Ranjana Advani
Saul A. Rosenberg, MD, Professor of Lymphoma
Hans-Christoph Becker, MD, FSABI, FSCCT
Clinical Professor, Radiology
Lauren Maeda
Clinical Associate Professor, Medicine - Oncology
Eligibility
Inclusion Criteria:
- Patients with newly diagnosed, CD30-positive mature T-cell lymphomas
- Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm
by CT
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Exclusion Criteria:
- History of another primary invasive malignancy that has not been in remission for at
least 3 years
- Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative
disorders and lymphomas or mycosis fungoides
- History of progressive multifocal leukoencephalopathy (PML)
- Cerebral/meningeal disease related to the underlying malignancy
Intervention(s):
drug: cyclophosphamide
drug: doxorubicin
drug: vincristine
drug: prednisone
drug: brentuximab vedotin
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061